International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
Rhesus testing and anti-D prophylaxis in RhD-negative women undergoing first-trimester abortion-Systematic Review and Opinion.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gemzell-Danielsson Kristina, Cameron Sharon, Bombas Teresa, Parachini Mirella, Lubusky Marek, Agostini Aubert, Kroeze Sandra, Favier Mary, Chebbah Myriam, Varlet Alice-Anaïs, Verhagen Linda, Fiala Christian
Аннотация
BACKGROUND: The introduction of immunoglobulin G (IgG) anti-D prophylaxis for Rhesus D (RhD)-negative women has substantially reduced the incidence of RhD alloimmunization and hemolytic disease of the fetus and newborn in Europe by 85%, transforming fetal health outcomes. However, there is little evidence for the need of giving IgG anti-D prophylaxis to RhD-negative women in first-trimester abortions.
OBJECTIVES: To analyze the international and national evidence-based guidelines on Rh testing and anti-D prophylaxis in first-trimester abortion, along with current literature both supporting and opposing this practice, to facilitate informed decision making in clinical practice.
SEARCH STRATEGY: A systematic search was conducted in Pubmed/MEDLINE, EMBASE, Cochrane Library, Google Scholar, and Gry literature for publications from January 1, 2003 to January 17, 2024.
SELECTION CRITERIA: Guidelines, reviews, meta-analyses, observational and qualitative studies, randomized trials, real-world data, and cohort studies that addressed the use of IgG anti-D prophylaxis in first-trimester abortions were included.
DATA COLLECTION AND ANALYSIS: Identified studies were screened and assessed independently by two authors. A standardized extraction grid was used to extract information from the selected articles.
MAIN RESULTS: Guidelines published from 2022 onwards, such as those from the World Health Organization, recommend against anti-D for women undergoing first-trimester abortion. In contrast, most older guidelines recommend RhD testing and the administration of IgG anti-D prophylaxis in abortions even before 12 weeks of amenorrhea, although exact gestational age thresholds vary widely. These discrepancies in the management of RhD-negative women undergoing first-trimester abortion are caused by different interpretations of the available evidence, IgG anti-D availability, cultural and social influences, as well as legal and regulatory considerations.
CONCLUSIONS: This review highlights the need for evidence-based, harmonized guidelines on IgG anti-D prophylaxis in first-trimester abortions. It is crucial for healthcare providers to stay informed on the latest recommendations and engage in shared decision-making with women undergoing first-trimester abortion.
OBJECTIVES: To analyze the international and national evidence-based guidelines on Rh testing and anti-D prophylaxis in first-trimester abortion, along with current literature both supporting and opposing this practice, to facilitate informed decision making in clinical practice.
SEARCH STRATEGY: A systematic search was conducted in Pubmed/MEDLINE, EMBASE, Cochrane Library, Google Scholar, and Gry literature for publications from January 1, 2003 to January 17, 2024.
SELECTION CRITERIA: Guidelines, reviews, meta-analyses, observational and qualitative studies, randomized trials, real-world data, and cohort studies that addressed the use of IgG anti-D prophylaxis in first-trimester abortions were included.
DATA COLLECTION AND ANALYSIS: Identified studies were screened and assessed independently by two authors. A standardized extraction grid was used to extract information from the selected articles.
MAIN RESULTS: Guidelines published from 2022 onwards, such as those from the World Health Organization, recommend against anti-D for women undergoing first-trimester abortion. In contrast, most older guidelines recommend RhD testing and the administration of IgG anti-D prophylaxis in abortions even before 12 weeks of amenorrhea, although exact gestational age thresholds vary widely. These discrepancies in the management of RhD-negative women undergoing first-trimester abortion are caused by different interpretations of the available evidence, IgG anti-D availability, cultural and social influences, as well as legal and regulatory considerations.
CONCLUSIONS: This review highlights the need for evidence-based, harmonized guidelines on IgG anti-D prophylaxis in first-trimester abortions. It is crucial for healthcare providers to stay informed on the latest recommendations and engage in shared decision-making with women undergoing first-trimester abortion.